Accelrys Announces Pfizer as the First Member of the Enterprise Cheminformatics Consortium
News Feb 02, 2007
The Consortium will be a collaborative software development project led by Accelrys in partnership with a group of commercial member organisations.
Its goal is to prioritise, design, and develop enterprise cheminformatics software components and services to allow members to implement industry-leading cheminformatics systems. The Consortium will commence in early 2007 and have three year duration.
"Close partnership and collaboration with industry is essential for Accelrys to develop software and services that help solve critical research problems," said Mark J. Emkjer, president and chief executive officer of Accelrys.
“We are delighted to have Pfizer join the consortium as our inaugural member and believe it will be instrumental in helping to guide the development of our next generation cheminformatics solutions that will address current and burgeoning research and development process and business challenges”.
This consortium initiative in the enterprise cheminformatics area will be an extension of the Accelrys consortium model, which in previous consortia has delivered important scientific advancements in areas such as catalysis, combinatorial chemistry, and nanotechnology.
The consortium model is a customer-centric approach to understand development needs. Consortium members collaborate in directing research and development activities that will result in products and services that solve important business issues and, accordingly, members will secure a period of exclusivity on the resulting consortium deliverables.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE